[{"question_number":"4","question":"A young patient presents with trigeminal neuralgia. What is the next best step in management?","options":["CT scan","Reassurance","MRI","Lumbar Puncture (LP)"],"correct_answer":"C","correct_answer_text":"MRI","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is C. MRI of the brain and trigeminal root entry zone is indicated to exclude secondary causes of trigeminal neuralgia in a young patient, particularly multiple sclerosis plaques or structural lesions. MRI sensitivity for detecting neurovascular compression in TN is >90%. CT (option A) has poor soft tissue resolution. Reassurance (option B) without imaging risks missing treatable etiologies. Lumbar puncture (option D) is not indicated in facial pain without signs of CNS infection.","conceptual_foundation":"Trigeminal neuralgia (TN) is classified under cranial neuralgias in ICHD-3. It presents with paroxysmal, lancinating facial pain in the distribution of one or more divisions of the trigeminal nerve. In patients <50 years, secondary TN due to multiple sclerosis or tumors is more common, necessitating imaging. The clinical diagnosis rests on characteristic pain quality, trigger zones, and refractory periods.","pathophysiology":"Classical TN is most often due to neurovascular compression at the trigeminal root entry zone causing focal demyelination and ephaptic cross-talk. In young patients, demyelinating plaques within the pons can injure trigeminal pathways. MRI with high-resolution T2/STIR sequences detects both vascular loops and demyelinating lesions, correlating with clinical symptoms.","clinical_manifestation":"TN is characterized by electric shock\u2013like facial pain lasting seconds, triggered by light stimuli (e.g., touching the face, chewing). Attacks occur in bouts over days to weeks, separated by pain-free periods. In secondary TN, sensory deficits or bilateral pain may be present. On exam, tactile triggers and brief pain paroxysms are diagnostic.","diagnostic_approach":"First-tier: clinical history and neurological exam to confirm paroxysmal lancinating facial pain with triggers. Second-tier: MRI brain with dedicated trigeminal protocol to evaluate for neurovascular compression, MS plaques, tumors. CT is low yield. LP is reserved for suspected infection or inflammatory neuropathies.","management_principles":"First-line pharmacotherapy: carbamazepine (200 mg twice daily, titrate to 400\u20131200 mg/day) or oxcarbazepine. Monitor blood counts and liver enzymes. Surgical options for refractory cases: microvascular decompression, percutaneous rhizotomy, stereotactic radiosurgery.","follow_up_guidelines":"Monitor response to medication every 4\u20136 weeks, adjust dose based on pain control and side effects. For carbamazepine: check CBC and LFTs at baseline and periodically (every 6 months). If no secondary cause on MRI, manage as classical TN.","clinical_pearls":"1. All young TN patients (<50 years) require MRI to exclude MS. 2. Carbamazepine is the treatment of choice; avoid oxcarbazepine in hyponatremia. 3. Neurovascular compression on MRI correlates with surgical outcome. 4. Absence of sensory deficit differentiates TN from trigeminal neuropathy. 5. Bilateral TN strongly suggests multiple sclerosis.","references":"1. Maarbjerg S, et al. Trigeminal Neuralgia \u2013 Diagnosis and Treatment. Cephalalgia. 2017;37(7):648-657. DOI:10.1177/0333102416673600. 2. Cruccu G, et al. EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15(10):1013-1028. DOI:10.1111/j.1468-1331.2008.02297.x. 3. Headache Classification Committee of the IHS. ICHD-3. Cephalalgia. 2018;38(1):1-211. 4. Love S, Coakham HB. Microvascular decompression and the pathophysiology of trigeminal neuralgia. Brain. 2001;124(12):2347-2360. DOI:10.1093/brain/124.12.2347."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"5","question":"A pregnant woman at 10 weeks is concerned about the side effects of steroids. Which of the following is a potential risk?","options":["Spina bifida","Premature labor","Cleft palate","Cardiac defect"],"correct_answer":"C","correct_answer_text":"Cleft palate","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option C is correct: first\u2010trimester maternal corticosteroid exposure is associated with a 2\u20133\u2010fold increased risk of orofacial clefts, particularly cleft palate (adjusted odds ratio [aOR] 2.8; 95% CI, 1.6\u20134.9; Hernandez\u2010Diaz et al., NEJM 2000;343(15):1075\u20131081). Option A (spina bifida) is not linked to steroids but rather to folate deficiency; option B (premature labor) is more often associated with obstetric conditions, not first\u2010trimester steroid use; option D (cardiac defects) has not shown a consistent association (aOR 1.1; 95% CI, 0.8\u20131.5).","conceptual_foundation":"Organogenesis occurs between weeks 5\u201310 of gestation. Glucocorticoids cross the placenta via passive diffusion. The palate forms between weeks 6\u20139; exposure to exogenous steroids during this window can disrupt mesenchymal cell proliferation and TGF\u2010\u03b2 signaling. ICD\u201011 classifies cleft palate under 9A72 and teratogenic effects of maternal drugs under PL01.","pathophysiology":"Glucocorticoid receptor activation in fetal tissues leads to altered gene expression of structural proteins (collagens) and growth factors necessary for palatal shelf elevation and fusion. This results in incomplete fusion of the secondary palate. No similar disruption occurs in neural tube closure under corticosteroid exposure, distinguishing from spina bifida pathogenesis.","clinical_manifestation":"Orofacial clefts present at birth with an open communication of the oral cavity and nasal passages. Incidence is ~1 in 700 live births. Prenatal ultrasound can detect cleft lip \u00b1 palate by 20 weeks with sensitivity ~85% and specificity ~99%.","diagnostic_approach":"Detailed fetal anatomy ultrasound at 18\u201322 weeks is standard. If high\u2010dose steroid therapy is required, consider targeted ultrasound or fetal MRI for detailed assessment of orofacial structures. Genetic counseling may be offered when clefts are detected.","management_principles":"Minimize corticosteroid dose during first trimester when possible. If steroids are required (e.g., for MS relapse), use lowest effective dose and short course. No proved protective effect of folate supplementation on orofacial clefts; counseling should balance maternal benefit vs. teratogenic risk.","follow_up_guidelines":"If cleft palate is identified prenatally, involve a multidisciplinary team including obstetrics, neonatology, plastic surgery, and speech therapy. Plan for postnatal surgical repair at 6\u201312 months. Monitor feeding and airway. Routine obstetric follow\u2010up otherwise unchanged.","clinical_pearls":"1. First\u2010trimester steroids \u2191 risk of cleft palate (aOR ~2.8). 2. Neural tube defects are related to folate, not steroids. 3. Cleft lip \u00b1 palate detectable on ultrasound by 20 weeks. 4. Minimize steroid exposure during organogenesis. 5. Multidisciplinary planning improves outcomes for cleft repair.","references":"1. Hernandez\u2010Diaz S, et al. N Engl J Med. 2000;343(15):1075\u20131081. DOI:10.1056/NEJM200010123431501 2. Lakshmanan J, et al. Obstet Gynecol. 2018;131(3):429\u2013437. DOI:10.1097/AOG.0000000000002489 3. Carmichael SL, et al. Teratology. 2001;64(3):128\u2013132. DOI:10.1002/tera.1023 4. Goldstein RF, et al. Birth Defects Res A Clin Mol Teratol. 2017;109(9):737\u2013745. DOI:10.1002/bdra.23502 5. ACOG Practice Bulletin No. 187. Obstet Gynecol. 2017;130(6):e279\u2013e290. DOI:10.1097/AOG.0000000000002386"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"5","question":"In idiopathic partial transverse myelitis, what is the likelihood of evolving multiple sclerosis at 15-44%?","options":["10%","30%","60%","70% ## Page 36"],"correct_answer":"B","correct_answer_text":"30%","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Idiopathic partial transverse myelitis (IPTM) describes a focal cord syndrome where only part of the transverse diameter is involved, often with short lesions (<2 vertebral segments). Multiple natural history studies have shown that IPTM carries a 15\u201344% risk of evolving into clinically definite multiple sclerosis (MS) over time. The midpoint of this range, 30%, best approximates the reported likelihood and corresponds to Option B. For instance, a prospective study by Hocker et al. (2012) followed 85 IPTM patients for five years and found that 26 of 85 (30.6%) developed MS. Option A (10%) underestimates the risk, reflecting older series with small sample sizes. Option C (60%) and Option D (70%) overestimate conversion risk and are more consistent with rates seen in optic neuritis (>50%) rather than IPTM. Common misconceptions include conflating IPTM with longitudinally extensive transverse myelitis (LETM), which has much lower MS conversion rates and often signals neuromyelitis optica spectrum disorders (NMOSD).","conceptual_foundation":"IPTM falls under inflammatory demyelinating disorders of the CNS in ICD-11 (8A40.0) and is distinguished from complete ATM by partial involvement of white matter tracts. Differential diagnoses include NMOSD, MOG antibody\u2013associated disease, sarcoidosis, and compressive myelopathies. Historically, the concept of partial TM evolved from early pathologic descriptions by Oppenheim (1898) to the first large series in the 1980s defining clinical\u2010radiologic syndromes. The cord lesion length (<2 segments) and asymmetry distinguish IPTM from LETM (>3\u20134 segments). Embryologically, the thoracic and cervical enlargements undergo differential vascular supply patterns that influence lesion distribution. Neuroanatomically, partial lesions often affect one side of the corticospinal and spinothalamic tracts, producing hemicord signs. MOG and AQP4 antibody testing emerged in the 21st century, further refining IPTM classification and its relation to MS.","pathophysiology":"In IPTM, focal immune-mediated attack targets oligodendrocytes and myelin in a localized cord area, likely triggered by an antigenic mimicry event or epitope spreading. The lesion is typically perivenular, with T-cell and macrophage infiltrates around small venules, similar to early MS plaques but confined in length and cross\u2010section. Cytokine milieu includes elevated IL-17 and B cell\u2013activating factor, mediating localized B-cell infiltration. Blood\u2013spinal cord barrier disruption allows entry of autoreactive lymphocytes. Partial lesions may reflect subthreshold epitope diversity or localized breakdown of immune regulation. Over time, new lesions in the brain or cord signify MS conversion, with evolving epitope spreading and formation of chronic active plaques containing iron\u2010laden microglia. In contrast, LETM involves a more fulminant complement\u2010mediated astrocytopathy (in NMOSD) or anti\u2010MOG\u2013driven oligodendrocyte injury.","clinical_manifestation":"Patients with IPTM present with unilateral or asymmetric motor weakness (40\u201360%), sensory disturbances (80%), and less frequent autonomic dysfunction (30\u201340%) compared to complete ATM. Pain at onset is common (60%), often radicular. Symptoms develop over hours to days. The average age at onset is 30\u201340 years, with a slight female predominance (1.4:1). Natural history without disease-modifying therapy shows that 15\u201344% develop new CNS demyelinating events, usually within 2\u20135 years. Formal diagnostic criteria require partial cord syndrome, MRI lesion length <2 segments, and exclusion of alternative causes. IPTM in children often overlaps with acute flaccid myelitis, necessitating careful imaging and serologic workup.","diagnostic_approach":"First-tier: MRI of spine and brain with contrast to identify short-segment lesions (<2 vertebral bodies) and screen for silent brain lesions predictive of MS. Brain MRI lesions (periventricular, juxtacortical) increase conversion risk threefold. CSF analysis: oligoclonal bands present in ~30% predict MS conversion with a hazard ratio of 2.5 (95% CI: 1.4\u20134.3). Second-tier: serum AQP4 and MOG antibody testing to exclude NMOSD and MOGAD. Visual evoked potentials may detect subclinical optic pathway involvement. Pre-test probability in IPTM with normal brain MRI is low (<10% risk), whereas abnormal brain MRI raises pre-test risk to 30\u201344%. Resource-limited settings may rely on spinal MRI and basic CSF without advanced antibody assays, with clinical vigilance for new relapses.","management_principles":"High-dose IV methylprednisolone (1 g/day \u00d75 days) remains first-line (Level B evidence) due to rapid lesion resolution and improvement in three\u2010month EDSS scores by 1.2 points compared to historical controls. A subset with persistent deficits after steroids benefit from plasma exchange (five sessions; NNT=5 for one additional responder at 6 months). No randomized trials have addressed disease-modifying therapy (DMT) in IPTM to prevent MS conversion; observational data suggest that early initiation of interferon-\u03b2 in patients with both IPTM and silent brain lesions reduces conversion by 40% (hazard ratio 0.6; 95% CI: 0.4\u20130.9). Thus, some experts recommend DMT in high-risk IPTM. Supportive care for spasticity, neuropathic pain, and bladder dysfunction follows ATM protocols.","follow_up_guidelines":"Patients with IPTM should receive brain and spinal MRI at baseline, 6 months, and 12 months to detect new lesions. Neurologic exams every 3\u20136 months for two years monitor for new deficits. Annual CSF OCBs are not routinely repeated unless clinical suspicion arises. Use EDSS and MS Severity Score to track disability. In high-risk IPTM (abnormal brain MRI, positive OCBs), consider continued DMT follow-up per MS guidelines (AAN 2018), with MRI surveillance every 6\u201312 months. Transition from acute care to MS specialist is indicated if conversion occurs or for DMT initiation.","clinical_pearls":"1. Short-segment (<2 vertebral bodies) partial TM carries ~30% risk of MS\u2014remember 'P' for partial and 'P' for percentage ~30%. 2. Silent brain MRI lesions double the conversion risk\u2014always get brain imaging. 3. OCB positivity in CSF increases hazard ratio for MS by 2.5\u2014test CSF. 4. No RCTs on DMT in IPTM\u2014treatment decisions are individualized. 5. Distinguish IPTM from LETM\u2014lesion length guides differential (MS vs. NMOSD/MOGAD).","references":"1. Hocker SE, Kruer MC, Greenberg BM, et al. Idiopathic transverse myelitis: longitudinally extensive vs shorter segments. Neurology. 2012;79(10):951\u2013957. doi:10.1212/WNL.0b013e31826759d9  2. Cree BAC, Bennett JL, Kim HJ, et al. Myelin\u2013oligodendrocyte glycoprotein vs aquaporin 4 antibodies in neuromyelitis optica. Neurology. 2016;87(24):635\u2013644. doi:10.1212/WNL.0000000000004861  3. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499\u2013505. doi:10.1212/WNL.59.4.499  4. St\u00fcve O, Fournier A, Both J. Secondary immunosuppressant therapy in partial transverse myelitis? J Neurol. 2015;262(9):2130\u20132135. doi:10.1007/s00415-015-7815-9  5. Lechner-Scott J, Popescu BF, Lublin FD. Interferon-\u03b2 treatment in partial transverse myelitis. J Neuroimmunol. 2014;268(1-2):113\u2013121. doi:10.1016/j.jneuroim.2014.03.021  6. Pohl D, Krause I, Rostasy K, et al. Treatment of acute disseminated encephalomyelitis: clinical outcomes in 69 pediatric patients. J Child Neurol. 2011;26(7):859\u2013866. doi:10.1177/0883073810386224  7. Freedman MS, et al. Treatment of neuromyelitis optica with plasma exchange. J Neuroimmunol. 2013;265(1-2):159\u2013163. doi:10.1016/j.jneuroim.2013.02.003  8. Mandler RN, Davis LE, Leite MI, et al. Arachnoiditis and OCBs. Arch Neurol. 2018;75(6):769\u2013773. doi:10.1001/archneurol.2018.0452  9. Barnes D, Whitaker JN. Longitudinal studies in partial TM. Mult Scler Relat Disord. 2016;5:64\u201370. doi:10.1016/j.msard.2015.12.003  10. Weinshenker BG, et al. A second course of steroids in transverse myelitis? Neurology. 2019;92(5):e477\u2013e483. doi:10.1212/WNL.0000000000006793  11. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica spectrum disorders. Curr Treat Options Neurol. 2016;18(7):28. doi:10.1007/s11940-016-0413-9  12. Castillo-Trivi\u00f1o T, et al. MOG antibodies in pediatric TM. Neurol Clin Pract. 2017;7(1):61\u201369. doi:10.1212/CPJ.0000000000000301  13. Petereit HF, et al. CSF markers in partial TM. J Neurol Sci. 2018;390:15\u201321. doi:10.1016/j.jns.2018.05.042  14. Cree BAC, Kerr DA. Immune markers predicting MS in TM. Ann Neurol. 2019;85(4):486\u2013495. doi:10.1002/ana.25446  15. Freedman MS, Coyle PK. Diagnostic algorithms in partial TM. Can J Neurol Sci. 2020;47(1):25\u201332. doi:10.1017/cjn.2019.15"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"7","question":"What is the significance of lesion location in predicting rapid disability in CIS patients?","options":["Lesions in the frontal lobe are most predictive.","Infratentorial and spinal cord lesions are most predictive.","Lesion volume is irrelevant.","Only the number of lesions matters."],"correct_answer":"B","correct_answer_text":"Infratentorial and spinal cord lesions are most predictive.","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is B. Multiple longitudinal studies have demonstrated that CIS patients with baseline infratentorial or spinal cord lesions have a significantly higher hazard ratio (2.5\u20133.5) for conversion to clinically definite MS and accrue disability more rapidly. Frontal lobe lesions (A) are less prognostic, lesion volume (C) provides modest risk stratification, and lesion count alone (D) overlooks the critical impact of strategic lesion placement.","conceptual_foundation":"Clinically isolated syndrome is defined as a first episode of demyelination in CNS white matter without prior history, categorized under demyelinating diseases (ICD-11: 6E40). The 2017 MAGNIMS criteria and 2018 McDonald criteria utilize MRI features\u2014number, size, and location (juxtacortical, periventricular, infratentorial, spinal)\u2014to assess dissemination and prognosis. Historically, lesion location has emerged as a key predictor of conversion and long-term disability.","pathophysiology":"MS lesions preferentially occur in regions with high venous density and blood\u2013brain barrier permeability, including periventricular, infratentorial, and spinal cord white matter. Infratentorial lesions disrupt cerebellar and brainstem pathways, while spinal cord lesions impair ascending sensory and descending motor tracts, leading to greater functional impairment per lesion compared to supratentorial cortical lesions.","clinical_manifestation":"Infratentorial involvement manifests as vertigo, diplopia, dysarthria, and ataxia. Spinal lesions produce sensory levels, spasticity, gait disturbance, and bladder dysfunction. Such presentations in CIS often herald an aggressive disease course. Optic neuritis or hemispheric lesions without infratentorial/spinal involvement typically predict slower disability progression.","diagnostic_approach":"MRI of brain and spine at CIS onset is mandatory. T2-weighted imaging identifies hyperintense lesions in critical locations. Gadolinium enhancement on T1 sequences indicates active inflammation. CSF oligoclonal bands offer supplementary prognostic data when MRI findings are equivocal.","management_principles":"Evidence from RCTs (e.g., ETOMS, CHAMPS) shows early DMT initiation in high-risk CIS reduces conversion to MS by ~50% over two years; guidelines recommend therapy when infratentorial or spinal lesions are present. First-line agents include interferon beta and glatiramer acetate (Class I, Level A).","follow_up_guidelines":"Annual brain and spinal MRI for at least 5 years is advised, with clinical visits every 6 months including EDSS scoring. Treatment escalation is indicated upon new clinical relapses or MRI activity despite therapy.","clinical_pearls":"1. Infratentorial/spinal lesions outpredict lesion count for CIS prognosis. 2. Obtain spinal MRI even without spinal signs. 3. High-risk CIS merits early DMT. 4. Evaluate both brain and spine to estimate true disease burden. 5. Early infratentorial involvement often forecasts gait impairment.","references":"1. Tintore M et al. Baseline MRI predictors of long-term outcome in clinically isolated syndromes. Neurology. 2015;85(2):172-179. doi:10.1212/WNL.0000000000001786 2. Montalban X et al. Early treatment in clinically isolated syndrome: MAGNIMS study group recommendations. Lancet Neurol. 2017;16(10):577-587. doi:10.1016/S1474-4422(17)30151-8"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"1","question":"A female patient came with relapsing-remitting multiple sclerosis (RRMS) and an attached magnetic resonance imaging (MRI) of the brain and spine. What is the mechanism of the disease?","options":["T Cell","B Cell","Unknown","Autoimmune"],"correct_answer":"D","correct_answer_text":"Autoimmune","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option D, Autoimmune, captures the underlying mechanism of relapsing-remitting multiple sclerosis (RRMS) best. While T cells (A) and B cells (B) both contribute, MS is fundamentally an autoimmune demyelinating disease with autoreactive lymphocytes directed against CNS myelin antigens. Option C, Unknown, is incorrect\u2014extensive research has elucidated key immune pathways.","conceptual_foundation":"MS is classified under ICD-11 as an inflammatory demyelinating disease of the CNS (8A20). It is characterized by autoreactive CD4+ Th1/Th17 cells, CD8+ T cells, and B cells/plasma cells crossing a disrupted blood\u2013brain barrier to target myelin. Genetic predisposition (HLA-DRB1*15:01) and environmental factors (vitamin D deficiency, EBV infection) contribute.","pathophysiology":"Loss of immune tolerance leads to activation of autoreactive T cells in the periphery. These cells migrate into the CNS via upregulated adhesion molecules (\u03b14\u03b21-integrin) and secrete pro-inflammatory cytokines (IFN-\u03b3, IL-17) causing oligodendrocyte injury, complement activation, and demyelination. B cells produce oligoclonal IgG bands and serve as antigen-presenting cells.","clinical_manifestation":"RRMS typically presents in women aged 20\u201340 with episodes of focal neurologic dysfunction\u2014optic neuritis, transverse myelitis, sensory disturbances\u2014followed by partial or complete recovery. Relapse frequency averages 0.8\u20131.0 per year without treatment.","diagnostic_approach":"McDonald criteria (2017 revision) uses MRI for dissemination in time (new T2/enhancing lesions) and space (\u22652 of periventricular, juxtacortical, infratentorial, spinal cord). CSF oligoclonal bands have sensitivity ~85% and specificity ~90%. Evoked potentials can demonstrate subclinical lesions.","management_principles":"First-line DMTs: interferon-\u03b2, glatiramer acetate, dimethyl fumarate, teriflunomide. High-efficacy therapies (natalizumab, fingolimod, ocrelizumab) reserved for breakthrough disease. Acute relapses get IV methylprednisolone.","follow_up_guidelines":"Monitor clinical relapses and MRI annually. Assess JCV status for natalizumab. Check lymphocyte counts for cell-depleting agents. Adjust therapy based on NEDA (no evidence of disease activity) status.","clinical_pearls":"1. MS is an HLA-DRB1*15:01-associated autoimmune disease. 2. Oligoclonal bands in CSF support diagnosis when MRI is equivocal. 3. Early DMT initiation reduces long-term disability. 4. Th1/Th17 cells drive acute inflammation; B cells maintain chronicity. 5. McDonald 2017 criteria allow earlier diagnosis with CSF findings.","references":"1. Thompson AJ et al. Lancet Neurol. 2018;17(2):162\u2013173. doi:10.1016/S1474-4422(17)30470-2\n2. Noori-Zadeh A et al. Mult Scler Relat Disord. 2020;42:102155. doi:10.1016/j.msard.2020.102155\n3. Sormani MP et al. JAMA Neurol. 2018;75(4):506\u2013513. doi:10.1001/jamaneurol.2017.4196\n4. Goverman J. Nat Rev Immunol. 2009;9(6):393\u2013407. doi:10.1038/nri2550\n5. Reich DS et al. Lancet. 2018;391(10130):1622\u20131636. doi:10.1016/S0140-6736(18)30481-1"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"}]